First Responder Program Advanced & Grant Milestone Achieved
Filed with ASX · · 5 pages · English
Summary by 6ix AI
EMvision Medical Devices Ltd. reports on the advancement of its First Responder program and the achievement of a grant milestone. The company has received ethics approval for two studies aimed at progressing its prototype brain scanner device towards commercialization. Additionally, EMvision has secured a non-dilutive milestone payment related to the development of the First Responder device under an agreement with the Australian Stroke Alliance.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
EMvision Medical Devices Ltd. on 6ix
Story so far
Earlier from EMvision Medical Devices
- Key Developments in Pivotal Trial & Innovation Study
- EMVision Awarded $5m Non-Dilutive Government Grant
- Additional Pivotal Trial Site Activations
- Enhanced Algorithm Performance From Continuous Innovation
- Activation of Second US Pivotal Trial Site, Mayo Clinic
Later from EMvision Medical Devices
- EMVision Awarded $3m Grant For Regional Benefits Study
- UCLA Health Activation & Continuous Innovation Study Update
- Appendix 4E & Annual Report to 30 June 2025
- Trading Halt
- Firm Commitments for $12.0M Placement & Launch of SPP
Follow EMvision Medical Devices into a list and get an email when it puts out news.
Follow EMvision Medical Devices